Story perspectives

New Flu Vaccine Targets Elderly's Weak Immune Response

9/9/2025

23 4

Summary

Story summary

Flu vaccines for individuals aged 65 and older will be available next month, focusing on high-risk groups.
Research indicates older adults produce more apolipoprotein D (ApoD), associated with increased flu severity.
High ApoD levels weaken immune responses, causing more tissue damage and lower resistance to influenza.
The study identifies ApoD as a potential target for therapies to reduce severe flu outcomes in the elderly.
Findings in PNAS stress the need for effective treatments as the global population ages.

1 of 1

Story summary

Flu vaccines for individuals aged 65 and older will be available next month, focusing on high-risk groups.
Research indicates older adults produce more apolipoprotein D (ApoD), associated with increased flu severity.
High ApoD levels weaken immune responses, causing more tissue damage and lower resistance to influenza.
The study identifies ApoD as a potential target for therapies to reduce severe flu outcomes in the elderly.
Findings in PNAS stress the need for effective treatments as the global population ages.